title: [Screening and management of coronary artery disease in diabetic patients].
abstract: Diabetes represents as independent risk factor for coronary artery disease (CAD) and the prognosis in term of survival rates is worse for diabetic patients who have CAD with report to those with CAD but no diabetes. The coronary artery disease in diabetes has specificities and, in particular, more extensive atherosclerosis. Diabetic patients are also more frequently asymptomatic. Due to the extreme complexity of ischemic vascular disease in patients with diabetes, an optimal therapeutic strategy is based on the correction of elevated blood glucose and lipid levels, of blood pressure, of platelet and coagulation abnormalities. Diabetic patients benefit from secondary prevention by drug therapy(aspirin, lipid lowering with statines, beta blocker and ACE inhibitors) to the same extent as, or more than, non-diabetic patients. Both percutaneous and surgical myocardial revascularization have been proved equally effective for CAD treatment in diabetes. A recent randomized trial has shown a significantly improved outcome after surgical revascularization. But, the effects of drug-eluting stents, which dramatically decrease the incidence of re-stenosis, seem promising.
authors.affiliation: Service de cardiologie, Hopiral Habib Thamteut, Tunis.
authors.forename: Sondos
authors.initials: S
authors.lastname: Kraiem
authors.forename: Chedly
authors.initials: C
authors.lastname: Abassi
authors.forename: Nizar
authors.initials: N
authors.lastname: Annabi
authors.forename: Ibtissem
authors.initials: I
authors.lastname: Smaali
authors.forename: Inès
authors.initials: I
authors.lastname: Issaa
authors.forename: Mouin
authors.initials: M
authors.lastname: Wali
authors.forename: Monia
authors.initials: M
authors.lastname: Malou
authors.forename: Sofiane
authors.initials: S
authors.lastname: Hannachi
authors.forename: Selma
authors.initials: S
authors.lastname: Longo
authors.forename: Kaies
authors.initials: K
authors.lastname: Battikh
authors.forename: Mohamed Lotfi
authors.initials: ML
authors.lastname: Slimane
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000175:diagnosis / Q000517:prevention & control / Q000601:surgery / Q000628:therapy; D023903:Coronary Restenosis / Q000517:prevention & control; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000150:complications* / Q000188:drug therapy; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications* / Q000188:drug therapy; D003925:Diabetic Angiopathies / Q000175:diagnosis / Q000517:prevention & control / Q000601:surgery / Q000628:therapy; D004569:Electroencephalography; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D008297:Male; D024821:Metabolic Syndrome / Q000150:complications; D008875:Middle Aged; D009204:Myocardial Revascularization; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D012306:Risk; D012307:Risk Factors; D015607:Stents; D016896:Treatment Outcome
chemical_list: D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000960:Hypolipidemic Agents; D010975:Platelet Aggregation Inhibitors; D001241:Aspirin